Literature DB >> 22411956

ECRG4 is a negative regulator of caspase-8-mediated apoptosis in human T-leukemia cells.

Junichi Matsuzaki1, Toshihiko Torigoe, Yoshihiko Hirohashi, Kenjiro Kamiguchi, Yasuaki Tamura, Tomohide Tsukahara, Terufumi Kubo, Akari Takahashi, Emiri Nakazawa, Eri Saka, Kazuyo Yasuda, Shuji Takahashi, Noriyuki Sato.   

Abstract

We previously established Fas-resistant variant clones from the human T-cell leukemia lines Jurkat and SUP-T13. Comparative gene expression analysis of the Fas-resistant and Fas-sensitive clones revealed several genes that were aberrantly expressed in the Fas-resistant clones. One of the genes, esophageal cancer-related gene 4 (ECRG4), contained a VDAC2-like domain that might be associated with apoptotic signals. In the present study, we examined the subcellular localization and function of ECRG4 in Fas-mediated apoptosis. By confocal fluorescence microscopy, ECRG4-EGFP fusion protein was detected in mitochondria, endoplasmic reticulum and the Golgi apparatus in gene-transfected HeLa cells. Overexpression of ECRG4 in Fas-sensitive Jurkat cells inhibited mitochondrial membrane permeability transition, leading to resistance against Fas-induced apoptosis. Tumor necrosis factor-alpha-induced apoptosis was also suppressed in ECRG4-overexpressing Jurkat cells. Immunoprecipitation assay demonstrated that ECRG4 is associated with procaspase-8. The inhibitory mechanism included the inhibition of caspase-8 activity and Bid cleavage. Since ECRG4 expression is downregulated in activated T cells, our results suggest that ECRG4 is a novel antiapoptotic gene which is involved in the negative regulation of caspase-8-mediated apoptosis in T cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22411956     DOI: 10.1093/carcin/bgs118

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  15 in total

1.  Downregulated ECRG4 is associated with poor prognosis in renal cell cancer and is regulated by promoter DNA methylation.

Authors:  Liya Luo; Jianting Wu; Jun Xie; Lingling Xia; Xuemin Qian; Zhiming Cai; Zesong Li
Journal:  Tumour Biol       Date:  2015-08-15

Review 2.  Potential functions of esophageal cancer-related gene-4 in the cardiovascular system.

Authors:  Rui Zhou; Yuanshu Liu; Wenjun Huang; Xitong Dang
Journal:  Front Med       Date:  2019-08-29       Impact factor: 4.592

3.  Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.

Authors:  Xitong Dang; Raul Coimbra; Liang Mao; Sonia Podvin; Xue Li; Hua Yu; Todd W Costantini; Xiaorong Zeng; Dana Larocca; Brian P Eliceiri; Andrew Baird
Journal:  Cell Mol Life Sci       Date:  2019-06-12       Impact factor: 9.261

4.  Soluble purified recombinant C2ORF40 protein inhibits esophageal cancer cell proliferation by inducing cell cycle G1 phase block.

Authors:  Xiaoyan Li; Linwei Li; Wenyu Wang; Yang Yang; Yun Zhou; Shixin Lu
Journal:  Oncol Lett       Date:  2015-06-26       Impact factor: 2.967

5.  A new brominated chalcone derivative suppresses the growth of gastric cancer cells in vitro and in vivo involving ROS mediated up-regulation of DR5 and 4 expression and apoptosis.

Authors:  Saiyang Zhang; Tingyu Li; Yanbing Zhang; Hongde Xu; Yongchun Li; Xiaolin Zi; Haiyang Yu; Jinfeng Li; Cheng-Yun Jin; Hong-Min Liu
Journal:  Toxicol Appl Pharmacol       Date:  2016-09-02       Impact factor: 4.219

6.  Cardiac Expression of Esophageal Cancer-Related Gene-4 is Regulated by Sp1 and is a Potential Early Target of Doxorubicin-Induced Cardiotoxicity.

Authors:  Dandan Long; Chunyue Chen; Wei Li; Wanling Peng; Dongmei Li; Rui Zhou; Xitong Dang
Journal:  Cardiovasc Toxicol       Date:  2022-02-07       Impact factor: 3.231

7.  Soluble purified recombinant C2ORF40 protein inhibits tumor cell growth in vivo by decreasing telomerase activity in esophageal squamous cell carcinoma.

Authors:  Linwei Li; Xiaoyan Li; Wenyu Wang; Tianhui Gao; Yun Zhou; Shixin Lu
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

8.  UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4.

Authors:  Jin Wang; Xiaomu Zhao; Lan Jin; Guocong Wu; Yingchi Yang
Journal:  Dig Dis Sci       Date:  2017-08-30       Impact factor: 3.199

9.  Ecrg4 attenuates the inflammatory proliferative response of mucosal epithelial cells to infection.

Authors:  Arwa Kurabi; Kwang Pak; Xitong Dang; Raul Coimbra; Brian P Eliceiri; Allen F Ryan; Andrew Baird
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

10.  ECRG4 expression in normal rat tissues: expression study and literature review.

Authors:  A Porzionato; M Rucinski; V Macchi; G Sarasin; L K Malendowicz; R De Caro
Journal:  Eur J Histochem       Date:  2015-05-18       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.